Navigation Links
Dynatronics Announces Fourth Quarter and Year-end Results
Date:9/28/2011

SALT LAKE CITY, Sept. 28, 2011 /PRNewswire/ -- Dynatronics Corporation (NASDAQ: DYNT) today announced results for its fiscal fourth quarter and year ended June 30, 2011.

Sales for the quarter ended June 30, 2011 increased 3 percent to $8,190,382, compared to $7,943,432 for the quarter ended June 30, 2010. Sales for the year ended June 30, 2011, were $32,692,859, down less than 1 percent from $32,962,392 for the prior year.

Net income for the quarter ended June 30, 2011 was $68,776 ($.01 per common share), compared to $70,955 ($.01 per common share) for the same quarter in the prior fiscal year. Net income for the year ended June 30, 2011 was $270,888 ($.02 per common share), compared to $423,977 ($.03 per common share) for the prior fiscal year.  Approximately $469,000 in increased research and development expenses primarily accounts for the lower profitability in fiscal year 2011.  

"Despite the fact R&D expenditures diminished our comparative profitability, such expenditures are important to enhancing future sales and maintaining our position as an innovator in the market," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics.  "In addition to our R&D initiative, we also made significant progress cultivating new sales opportunities with Group Purchasing Organizations (GPOs) and national accounts.  During the year, we announced the signing of contracts with four GPOs: Premier, Amerinet, First Choice and Champs Group Purchasing.  These contracts became effective in the latter part of the fiscal year and we have begun the process of introducing GPO member facilities to Dynatronics' brand of products."

"The contracts with the GPOs represent a license to solicit business directly from the members of the respective GPOs," explained Cullimore.  "While initial indications of interest from these new GPO cu
'/>"/>

SOURCE Dynatronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dynatronics to Release Fiscal Fourth Quarter and Year-end Results Wednesday, September 28, 2011; Conference Call Set for 1:00 p.m. ET
2. Dynatronics Appoints Bryan D. Alsop Vice President of Information Technology
3. Dynatronics Signs Agreement With CHAMPS Group Purchasing
4. Dynatronics Third Quarter Profits Increase 22%
5. Dynatronics to Release Fiscal Third Quarter Results Monday, May 16, 2011; Conference Call Set for 1:00 p.m. ET
6. Dynatronics Regains Compliance With NASDAQ
7. Dynatronics Selected for Inclusion in RB Milestone Portfolio
8. Dynatronics Signs Third GPO Contract in Two Months
9. Dynatronics Announces $1 Million Stock Buyback Program
10. Dynatronics Announces Fiscal Second Quarter Results
11. Dynatronics to Release Fiscal Second Quarter Results Monday, February 14, 2011; Conference Call Set for 1:30 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... LAKE, N.J. , May 30, 2015  Eisai Inc. ... 309), which showed that eribulin met the study,s primary endpoint ... or adipocytic sarcoma (ADI), two types of advanced soft tissue ... Annual Meeting of the American Society of Clinical Oncology ... the ASCO press conference on Saturday, May 30, and also ...
(Date:5/30/2015)... May 30, 2015 Caris Life Sciences®, ... promise of precision medicine, today announced the presentation ... utility of Caris Molecular Intelligence®, the company,s panomic ... tumors that share histological features. In separate presentations ... of Clinical Oncology (ASCO) in Chicago, ...
(Date:5/29/2015)... May 29, 2015 /CNW/ - Alliance Principle Ingredients/Neutrical Solutions ... the health product Galenic Health Ginger in Bentonite ... for adolescents and children. The product currently contains ... but within acceptable limits for adult dosing. ... digestive upset and disturbances. Alliance Principle Ingredients / ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
(Date:5/30/2015)... 2015 Promising clinical trial results presented ... Meeting 2015 show activity of the investigational anti-cancer agent ... against brain metastases and in another case in overall ... "I am thrilled to have been able to offer ... She didn't have any other great treatment options that ...
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 NovaSure® endometrial ... lighten or stop periods, without the side effects ... can reduce or stop menstrual bleeding and works by ... (the part that causes the bleeding), with a quick ... suffer from heavy menstrual bleeding. Many women begin ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The results ... crocidolite asbestos has a high potential to cause mesothelioma, ... full story now on the Surviving Mesothelioma website. ... of Occupational Medicine in Lodz, Poland found that, among ... workers between 1970 and 2012, all of them happened ...
(Date:5/30/2015)... 30, 2015 One of the pervasive ... local healthcare options available. Often, the ruralness of a ... those in rural areas feeling the crunch of a ... or tired of paying high premiums and copays, ... with licensed physicians via the power of the internet. ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3
... at the place of work, according to a recent study ... between stress and poor health has also been identified by ... metabolic syndrome and stress among the 10,000 civil servants belonging ... who were studied, which also involves high blood pressure and ...
... Indian population. This disease is due to the inability of the ... be due to the inability of the body to maintain normal ... slight modification in the lifestyle can help the patients to tackle ... Hospital for Diabetes Research Center, Royapuram and was headed by the ...
... at the Max Planck Institute for Developmental Biology in Tübingen (now ... able to identify a // protein that seems to play a ... ,The protein called Staufen2, appears to play a ... if this protein was blocked out from a nerve cell, it ...
... Iceland-based Ossur hf., a global orthopaedics company, has acquired ... $ 38.4 million. ,The acquisition of Innovation ... acquisition// of Royce Medical in the U.S., and the ... With these acquisitions, and its 2003 acquisition of Generation ...
... Comprehensive Cancer Center – Arthur G. James Cancer Hospital ... tumor suppressor gene that could be of vital significance ... well as lung cancer. //Their study shows that activating ... the aforementioned cancers. ,The gene, called TCF21 is ...
... available to Canadians from supermarkets and corner stores as a ... from making crystal meth. //The supermarkets and drug stores which ... which will come into force from 10 April 2006. Only ... are of the single ingredient category. This is inclusive of ...
Cached Medicine News:Health News:Protein Found to Be Essential For Maintaining Nerve Health 2Health News:Ossur Acquires the U.S. Orthopaedics Company 2Health News:Unusual Tumor-Suppressor Gene Switches Off in Lung Cancer 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
... The Vitek is a completely automated instrument ... of 2 - 6 hour same day ... quality control module. It is used for ... and urine screening and has a complete ...
IDS Rapid One, a microbial identification system....
Medicine Products: